Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma
Authors:
- Danielle MaeserDMDanielle Maeser
- Robert F. GruenerRGRobert F. Gruener
- Robert GalvinRGRobert Galvin
- Adam LeeALAdam Lee
- Tomoyuki KogaTKTomoyuki Koga
- Florina-Nicoleta GrigoreFGFlorina-Nicoleta Grigore
- Yuta SuzukiYSYuta Suzuki
- Frank B. FurnariFFFrank B. Furnari
- Clark ChenCCClark Chen
- R. Stephanie HuangRHR. Stephanie Huang
Open Access
Abstract
Glioblastoma multiforme (GBM) is the deadliest, most heterogeneous, and most common brain cancer in adults. Not only is there an urgent need to identify efficacious therapeutics, but there is also a great need to pair these therapeutics with biomarkers that can help tailor treatment to the right patient populations. We built patient drug response models by integrating patient tumor transcriptome data with high-throughput cell line drug screening data as well as Bayesian networks to infer relationships between patient gene expression and drug response. Through these discovery pipelines, we identified agents of interest for GBM to be effective across five independent patient cohorts and in a mouse avatar model: among them are a number of MEK inhibitors (MEKis). We also predicted phosphoglycerate dehydrogenase enzyme (PHGDH) gene expression levels to be causally associated with MEKi efficacy, where knockdown of this gene increased tumor sensitivity to MEKi and overexpression led to MEKi resistance. Overall, our work demonstrated the power of integrating computational approaches. In doing so, we quickly nominated several drugs with varying known mechanisms of action that can efficaciously target GBM. By simultaneously identifying biomarkers with these drugs, we also provide tools to select the right patient populations for subsequent evaluation.Keywords
Funding Information
- NIH/NCI grants (R01CA204856, R01CA229618, 75N91019D00024)
- NCI Contract (R01CA204856, R01CA229618, 75N91019D00024)
- University of Minnesota (UMN) OACA Faculty Research Development grant (R01CA204856, R01CA229618, 75N91019D00024)
- UMN OACA GIA award (R01CA204856, R01CA229618, 75N91019D00024)
- UMN College of Pharmacy (COP) SURRGE award (R01CA204856, R01CA229618, 75N91019D00024)
- UMN Masonic Cancer Center (MCC) CRTI Exceptional Translational Research Award (R01CA204856, R01CA229618, 75N91019D00024)
This publication has 35 references indexed in Scilit:
- Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma PatientsGenomics, Proteomics & Bioinformatics, 2021
- Drug Resistant Melanoma May Be Vulnerable to Inhibitors of Serine SynthesisJournal of Investigative Dermatology, 2020
- Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase InhibitionJournal of Investigative Dermatology, 2020
- The limitations of targeting MEK signalling in Glioblastoma therapyScientific Reports, 2020
- Longitudinal assessment of tumor development using cancer avatars derived from genetically engineered pluripotent stem cellsNature Communications, 2020
- Pharmacogenomic agreement between two cancer cell line data setsNature, 2015
- Normalization of RNA-seq data using factor analysis of control genes or samplesNature Biotechnology, 2014
- An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small MoleculesCell, 2013
- Long-term survival of patients with glioblastoma multiforme (GBM)Journal of Clinical Neuroscience, 2013
- Genetic wrappers for feature selection in decision tree induction and variable ordering in Bayesian network structure learningInformation Sciences, 2004